Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 13/20 | 0.46 |
| ▸ | MMP2 | P08253 | 4/20 | 0.46 |
| ▸ | MMP13 | P45452 | 2/20 | 0.46 |
| ▸ | MMP14 | P50281 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 2/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4339658 | 0.90 | ADAM17 (0.42) | ADAM17MMP2MMP13MMP14ALDH1A1 | |
| SCHEMBL4333067 | 0.90 | ADAM17 (0.45) | ADAM17MMP2MMP13MMP14KMT2A | |
| SCHEMBL4336056 | 0.87 | ADAM17 (0.46) | ADAM17MMP2MMP13MMP14ALDH1A1 | |
| SCHEMBL13819394 | 0.83 | CHRM1 (0.56) | ADAM17MMP2MMP13MMP14KMT2A | |
| SCHEMBL4332251 | 0.82 | ADAM17 (0.47) | ADAM17ALDH1A1MAPTRECQL | |
| SCHEMBL4335269 | 0.79 | MCL1 (0.41) | ADAM17MMP2MMP13MMP14KMT2A | |
| SCHEMBL4333236 | 0.79 | MEN1 (0.52) | MEN1KMT2AMAPT | |
| SCHEMBL13819822 | 0.77 | MAPT (0.51) | ADAM17MMP2MMP13MMP14KMT2A | |
| SCHEMBL13819345 | 0.73 | KMT2A (0.53) | ADAM17KMT2AALDH1A1MAPT | |
| SCHEMBL4333208 | 0.70 | CREBBP (0.42) | MEN1KMT2AALDH1A1MAPTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | GPR119, IRS1, SLC5A1 | ADAM17 4781/4885MMP2 2991/4885MMP13 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.